

UCSF

UC San Francisco Previously Published Works

Title

Stimulant use for Self-Management of Pain among Safety-Net Patients with Chronic Non-Cancer Pain

Permalink

<https://escholarship.org/uc/item/91z412hn>

Journal

Substance Use & Addiction Journal, 43(1)

ISSN

2976-7342

Authors

Beliveau, Cathleen M

McMahan, Vanessa M

Arenander, Justine

et al.

Publication Date

2022-12-01

DOI

10.1080/08897077.2021.1903654

Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial License, available at <https://creativecommons.org/licenses/by-nc/4.0/>

Peer reviewed

Stimulant use for self-management of pain among safety-net patients with chronic non-cancer pain.

Cathleen M. Beliveau, BA ¹

Vanessa M. McMahan, PhD, MS ¹

Justine Arenander, MSW ¹

Martin S. Angst, MD ²

Margot Kushel, MD ³

Andrea Torres, BA ¹

Glenn-Milo Santos, PhD, MPH ^{1, 3}

Phillip O. Coffin, MD, MIA ^{1, 3}

¹ San Francisco Department of Public Health, San Francisco, CA, USA.

² Department of Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, USA.

³ University of California San Francisco, San Francisco, CA, USA.

Corresponding author: Cathleen Beliveau, 25 Van Ness Ave, San Francisco, CA 94102. Phone: (628) 217-6321, email:

cathleen.beliveau@sfdph.org, website: <https://www.csuhsf.org/>

Sources of support: This work was supported by National Institutes of Health grants R01DA040189 and K24DA042720.

Declarations of interest: none

21 pages; 3 tables

Abstract (250/250 words)

Background: Chronic pain affects one-fifth of US adults. Reductions in opioid prescribing have been associated with increased illicit opioid use and, chronologically, increased illicit stimulant (methamphetamine and cocaine) use. While illicit opioid use is commonly attributed to pain self-management, the role of stimulants is unclear.

Methods: We analyzed baseline data from a longitudinal study of patients with chronic non-cancer pain (N=300) to estimate the prevalence and identify correlates of stimulant use to treat pain. Data sources included questionnaire (demographics, substance use, pain), clinical exam and procedures (pain, pain tolerance), and chart abstraction (opioid prescriptions). We conducted bivariate analyses to assess if demographics, pain characteristics and management, substance use, opioid prescriptions, and self-reported symptoms were associated with reporting using stimulants to treat pain. Demographic variables and those with significant bivariate associations were included in a multivariable logistic regression model.

Results: Fifty-two percent of participants with past-year stimulant use reported using stimulants in the past year to treat pain. Participants who used stimulants for pain reported slightly higher average pain in the past 3 months (8 vs 7 out of 10, $p=0.049$). In multivariable analysis, female gender (AOR= 3.20, 95% CI: 1.06-9.63, $p=0.039$) and higher score on the *Douleur*

Neuropathique 4 neuropathic pain questionnaire (AOR= 1.34, 95% CI: 1.05-1.70, p=0.017) were associated with past-year stimulant use to treat pain.

Conclusion: Stimulants may be used for pain self-management, particularly for neuropathic pain and among women. Our findings suggest an underexplored motivation for stimulant use in an era of reduced access to prescribed opioids.

Keywords: chronic pain; pain management; stimulants; methamphetamine; cocaine; safety-net clinic

1. Introduction

Chronic pain is prevalent, difficult to manage, and disproportionately affects socioeconomically disadvantaged populations (Dahlhamer et al., 2018). As of 2016, 20.4% of U.S. adults suffered from chronic pain and 8% had associated disability (Dahlhamer et al., 2018). Meanwhile, from 2012-2018, the per capita rate of opioid prescribing declined from 81.3 to 51.4 prescriptions per 100 persons (Centers for Disease Control and Prevention, 2020). The reduction in opioid prescribing has been associated with increased illicit opioid use (Coffin et al., 2020) and, chronologically, increased illicit stimulant use (Centers for Disease Control and Prevention, 2012, 2015; Coffin et al., 2019; John and Wu, 2017). While increased illicit opioid use often has been attributed to self-management of pain or opioid use disorder, there is less clarity regarding the increase in stimulant use (Behar et al., 2020; Voon et al., 2014).

Clinical and *in vivo* lab studies across a range of pain types suggest that stimulants may possess some analgesic properties (Camarasa et al., 2009; Forrest et al., 1977; Jasinski and Preston, 1986; Lin et al., 1989; Pud et al., 2017). Qualitative studies have found that some people living with HIV report using cocaine or methamphetamine to manage their pain (Behar et al., 2020; Merlin et al., 2015; Robinson and Rempel, 2006). In addition, the neuropeptide CART (cocaine- and amphetamine-regulated transcript) has been implicated in the regulation of neuropathic pain (Ahmadian-Moghadam et al., 2018; Upadhyaya et al., 2011).

To examine a possible relationship between stimulant use and pain management among persons with chronic pain, we performed an exploratory analysis of characteristics associated with reporting stimulant use to treat pain among patients enrolled in the Cohort Study of Opioids, Pain, and Safety in an era of Changing Policy (COPING) study. A clearer understanding of the effects of stimulants as a method of pain self-management is important to ensure that healthcare providers understand motivations for stimulant use and integrate such knowledge into devising effective and safe pain management strategies.

2. Materials and Methods

2.1 Data Source and Sample

We used baseline data from COPING, a longitudinal cohort study assessing changes in pain, functional status, and illicit substance use in response to changes in prescribed opioid availability among patients with chronic non-cancer pain (CNCP). COPING enrolled 300 patients from a safety net healthcare system in San Francisco that accepts only publicly insured or uninsured patients. Study participants were eligible for the study if they had CNCP, had been prescribed an opioid for at least 3 of the last 12 months prior to enrollment, and had a lifetime history of illicit opioid, cocaine, or amphetamine use. CNCP was defined as chronic pain that was not due to active cancer, as identified by review of electronic medical records. All participants provided informed consent prior to participation and were seen at enrollment and annually thereafter. Enrollment visits occurred from March

28, 2017 through March 6, 2019. The study was approved by the University of California San Francisco Institutional Review Board (IRB# 15-18274).

At all visits, participants underwent clinical examination and computer assisted personal interview (CAPI). Experiences of pain were assessed through CAPI and exam, including *Douleur Neuropathique 4* (DN4) (Bouhassira et al., 2005) assessment and cold pressor test (CPT) (Modir and Wallace, 2010). Demographics, substance use, mood, pain management, and prescription opioid use were assessed by CAPI. At enrollment and biannually, participants' electronic medical records were abstracted for information on medical conditions and prescriptions. Participants received \$50 for each study visit. The study was approved by the University of California, San Francisco Committee on Human Research (# 15-18274).

2.2 Measurements

2.2.1 *Stimulant Use*

Participants were considered to have used stimulants in the past year if they reported any use of methamphetamine, cocaine, or crack cocaine in the prior year on the CAPI. Participants reporting past-year methamphetamine or speed use were asked if they had used either to treat their pain during the past year; the same question was asked of those reporting cocaine or crack cocaine use. Participants were categorized as using stimulants to treat their pain if they reported "yes" to either question.

2.2.2 *Sociodemographic Characteristics*

Sociodemographic characteristics from the CAPI included age (continuous), sex at birth (female, male, intersex), gender (female, male, transgender, and other), race (African American or Black; Asian American or Pacific Islander; Native American, American Indian, or Alaskan Native; White, Caucasian, or European American; Mixed or Multi-racial; Other), ethnicity (Hispanic or non-Hispanic), highest level of education attained, annual pre-tax income, and ever being homeless (yes/no). The proportion of participants who reported that they were housed (“in my own house or apartment,” “in someone else’s house or apartment,” or “rented room (hotel or rooming house)”) or stayed outside (“car, bus, truck, or other vehicle” or “on the streets”) for most of the prior year was reported. We collapsed race into three categories (White, Caucasian, or European American; African American or Black; or Other) due to small numbers in some categories. We similarly collapsed highest level of education into a two-level measurement (high school or GED or less, some college or more) and annual income into three categories (\$0-9,999, \$10,000-19,999, >\$20,000).

2.2.3 Clinical and Self-Reported Pain Measurements

We used three measurements of pain: the DN4 screening tool, self-reported average pain over the past 3 months (a 0-10 scale), and pain catastrophizing. The DN4 is a screening tool for neuropathic pain, which consists of a patient interview and a clinical examination with 10 questions (Bouhassira et al., 2005; Spallone et al., 2012). The CAPI assessed pain characteristics (burning, painful cold, and electric shocks) and pain

symptoms (tingling, pins and needles, numbness, and itching) in the same area. Sensory deficits and evoked pain were assessed by clinical examination in the area of the body the participant identified as their primary pain location. Hypoesthesia was assessed by numbness either when the area was pressed by hand or pricked by the wood end of a cotton-tipped applicator. Allodynia was assessed by pain that was caused or increased by brushing the area with the cotton end of the applicator. DN4 scores were included both continuously and as a binary variable using the validated cut-off of 4 (<4 no neuropathic pain vs ≥ 4 neuropathic pain) (Spallone et al., 2012).

Average pain over the past 3 months (a 0-10 scale) and pain catastrophizing were self-reported via the CAPI. The Pain Catastrophizing Scale prompted respondents to think about past painful experiences while responding to 13 items that assess pain magnification and rumination, as well as feelings of helplessness related to pain; responses were on a 5-point scale ("not at all," "to a slight degree," "to a moderate degree," "to a great degree," and "all the time"). Scores were summed and total scores of 30 or greater were defined as pain catastrophizing, based on research from the University Centre for Research on Pain and Disability, to create a binary variable of clinical relevance (pain catastrophizing versus none) (Michael J.L Sullivan, 1995).

2.2.4 *Cold Pressor Test*

The CPT involved a temperature-controlled circulating water bath set to 2.0°C to measure participants' cold pain threshold and tolerance. Participants were instructed to place their hand flat on the bottom and report when they first felt a dull, achy pain ("cold pain threshold") and then remove their hand from the water when they were unable to tolerate the pain. The "cold pain tolerance" was the full time the hand was submerged (Oaks et al., 2018; Treister et al., 2015). The CPT was repeated until the cold pain threshold and total time of hand submersion were within 20% of the prior test, up to 5 trials, with at least 20 minutes between trials. Participants could refuse all or some of the CPT tests, so not all recorded scores were within 20% of the previous test. The cold pain threshold and tolerance, measured in seconds, from participants' final CPT at enrollment were included in this analysis.

2.2.5 *Substance Use Covariates*

Frequency of stimulant use was collected via two separate questions in the CAPI, assessing methamphetamine or speed use and cocaine or crack cocaine use. Each question had six possible answer options. We defined the frequency of stimulant use as the higher frequency reported across these two questions. We then collapsed responses into two categories (less than weekly versus at least weekly) due to small sample sizes in some categories. We defined any past year injection (yes/no) as reporting injection of any substance in the past year.

Prescribed opioid dose for pain management was assessed as morphine milligram equivalents (MMEs), converted following guidelines from the US Centers for Disease Control and Prevention and the Australian National Drug and Alcohol Research Centre (Centers for Disease Control and Prevention, 2019; Nielsen et al., 2016). We used opioid prescription data from medical chart abstraction to calculate daily MME for each participant for the year preceding enrollment and reported the maximum MME during that time. We considered a participant to have had an opioid discontinuation if they had a non-zero MME a year before enrollment and were prescribed no opioids for pain at enrollment.

2.2.6 Post-Traumatic Stress Disorder, Depression, and Psychological Distress

We included scales in the CAPI measuring post-traumatic stress disorder (PTSD), depression, and psychological distress. Participants were considered to have PTSD if they answered “yes” to at least three of the four items in the Primary Care PTSD Screen (PC-PTSD), a brief screening tool designed for use in medical settings (Prins et al., 2003; Spoont et al., 2015). Depression was assessed with the Patient Health Questionnaire-8 depression scale (PHQ8), a valid and widely-used measure assessing the frequency (“not at all,” “several days,” “more than half the days,” “nearly every day”) of being bothered by depressive symptoms over the past two weeks (Kroenke et al., 2001). We summed all items to calculate total scores and categorized responses as depressed (≥ 10) vs not depressed (< 10) (Kroenke et al., 2009; Wu et al., 2019). Psychological distress was measured using continuous

scores from the Brief Symptom Inventory 18 (BSI-18), an 18-item screen with three subscales (somatization, depression, and anxiety) (Derogatis and Fitzpatrick, 2004).

2.2.7 Non-opioid Medications and Complementary Therapies

Participants were asked which non-opioid medications they were prescribed to treat their pain at the time of enrollment on the CAPI. Medications were categorized as “none,” “neuropathic pain medications” (lidocaine patch/cream, capsaicin cream, amitriptyline, nortriptyline, gabapentin, pregabalin, valproic acid, topiramate, duloxetine, venlafaxine, cyclobenzaprine, methocarbamol, baclofen, carisoprodol), “medical marijuana,” and “other non-opioid medications to treat pain” (acetaminophen formulations without opioids, nonsteroidal anti-inflammatory drugs [NSAIDs], ergotamine, sumatriptan, butalbital formulations, tramadol). Any past-year use of non-medication pain management therapies (chiropractic, physical/occupational therapy, acupuncture, massage therapy, counseling) was also assessed by CAPI.

2.2.8 Statistical Analysis

We conducted bivariate analyses comparing sociodemographic characteristics by past-year stimulant use and, among those who had used stimulants in the past year, by whether or not they reported using stimulants to treat pain during that year. We also compared substance use, opioid prescriptions, pain characteristics and management, Brief Symptom

Inventory, depression, and PTSD by whether or not participants who used stimulants in the past year had used them to treat pain or not. Comparisons of categorical variables were made using the Pearson chi-square test and Fisher's exact test for expected cell counts less than five. Continuous variables were compared using t tests for variables with a normal distribution and Wilcoxon rank sum tests for skewed variables.

We used a multivariable logistic regression model to further assess associations between participant characteristics and reporting stimulant use for pain. The model included demographic characteristics (age, gender, race) and pain and mood covariates that were significant in bivariate analyses. We used a post-estimation command to rescale the age variable to report an adjusted odds ratio (AOR) of an increase of 10 years. All analyses were performed in Stata Version 14 (Stata Corp, College Station, TX). A p-value of less than 0.05 was considered statistically significant.

3. Results

The mean age of all COPING participants (N=300) at enrollment was 57 years (standard deviation [SD] \pm 8.2), 61% reported male gender, and 77% had experienced homelessness. Almost half of the cohort was Black/African-American (45%), approximately one-third was White/Caucasian (34%), and the rest reported other or multiracial race (21%); 11% of the cohort self-identified as Latinx/Hispanic. Of the 300 participants, 105 (35%) reported illicit stimulant use in the past year. Of these, 37% had used cocaine or crack but no methamphetamine or speed, 31% had used methamphetamine or

speed but no cocaine or crack, and 31% had used both in the past year. Those reporting past-year stimulant use were slightly younger (mean age of 56 [SD± 8.5] vs 58 [SD± 7.9], $p=0.007$); a higher proportion were male (69% vs 56%, $p=0.04$), HIV-positive (54% vs 25%, $p<0.001$), and reported ever being homeless (86% vs 72%, $p=0.007$). The majority (92%) of participants who used stimulants reported being housed for most of the past year; no significant past-year differences were detected across groups.

Fifty-two percent of those reporting past-year stimulant use reported using stimulants to treat their pain. Demographic characteristics by past-year use of stimulants to treat pain are shown in Table 1. Compared to participants who used stimulants in the past year but did not report using them for pain, a higher proportion of participants who used stimulants to treat pain reported higher education (62% vs 42%, $p=0.04$) and ever being homeless (93% vs 78%, $p=0.03$).

Table 2 shows pain characteristics, use of non-opioid medications and therapies, substance use, and self-reported symptoms by past-year use of stimulants to treat pain. Participants who reported using stimulants to treat pain reported slightly higher average pain in the past 3 months (median of 8 [IQR: 7-9] vs 7 [6-8], $p=0.049$) and DN4 score (mean of 4.45 [SD± 2.28] vs 3.42 [SD± 2.04], $p=0.017$). A higher proportion of participants who reported stimulants to treat pain in the past year reported depression (49% vs 28%, $p=0.027$). We did not detect a difference by CPT in cold pain threshold (median of 7.48 [IQR: 5.21-11.9] vs 8.03 [5.5-10.4], $p=0.93$) or cold pain

tolerance (median of 13.2 [IQR: 7.98-20.7] vs 13.0 [8.61-18.9], $p=0.87$), when comparing participants who reported stimulant use for pain to those who did not. We did not detect a difference in use of neuropathic pain medications or medical marijuana across groups, but a higher proportion of people who used stimulants for pain reported being prescribed “other” non-opioid medications to treat pain (e.g., acetaminophen, NSAIDs) (42% vs 20%, $p=0.016$).

In the multivariable regression, DN4 score and female gender were significantly associated with using stimulants to treat pain in the past year, while controlling for age, race, highest level of education attained, ever being homeless, average pain in the past three months, depression, and other non-opioid medications to treat pain in the model. Every increase of one point on the DN4 scale was associated with 1.34 times the odds of reporting stimulants to treat pain (95% CI: 1.05-1.70, $p=0.017$); participants reporting female gender had 3.20 times the odds of reporting stimulants to treat pain compared to those reporting male gender (95% CI: 1.06-9.63, $p=0.039$). (Table 3)

4. Discussion

The majority of participants with CNCP who used stimulants in the past year reported using them to treat pain. This finding builds upon qualitative data suggesting that stimulants play a role in pain self-management for patients living with HIV and chronic pain (Behar et al., 2020; Robinson and Rempel, 2006), and extends that finding to HIV-negative patients. In the

setting of reduced opioid prescribing, stimulants may play a role in self-directed pain management, particularly among patients who have a history of substance use and lack sufficient access to medically-directed pain management. To our knowledge, no other studies have examined the relationship between clinical pain characteristics and using stimulants for pain.

Our findings reveal a potential relationship between neuropathic pain and stimulant use to treat pain. Specifically, we observed an association between the number of neuropathic pain attributes used by participants to describe their pain and their use of stimulants to treat pain. A qualitative study (Robinson and Rempel, 2006) documented methamphetamine use to treat neuropathic pain in a small cohort of HIV-positive men. Notably, half of the HIV-positive participants in our cohort used stimulants to treat pain, suggesting that HIV-associated pain, which is neuropathic in nature, may be one reason for illicit stimulant use. The previously described role of neuropeptide CART in regulating neuropathic pain further supports the potential benefit of these agents in neuropathic pain syndromes (Ahmadian-Moghadam et al., 2018; Upadhyaya et al., 2011). Patients with neuropathic pain may be particularly prone to the use of stimulants as a strategy to self-manage pain.

In our cohort, women who use stimulants were more likely than men who use stimulants to report using them for pain management. Chronic pain with neuropathic characteristics has been found to be more prevalent in

women than in men (Bouhassira et al., 2008; Dieleman et al., 2008; Torrance et al., 2006) but stimulant use for pain was higher in women even when controlling for neuropathic pain characteristics. Future studies of stimulant use for the treatment of pain should represent many gender identities as there may be gender-specific differences.

Stimulants may also be used to improve daily functional status or help prevent social harms. For example, stimulant use has been shown to have a targeted role among people experiencing homelessness by reducing the need for sleep and thus lowering safety risks associated with living outside (Al-Tayyib et al., 2017; Bungay et al., 2006). It is possible that in this chronic pain population, stimulant use may be associated with improved overall functioning, and that this improvement could reduce experiences of pain.

Using stimulants to treat pain may have benefits for co-occurring conditions. While not significant in the multivariable analysis, in the bivariate analysis we saw a higher proportion of participants who reported moderate to severe depression among people who used stimulants to treat pain in the past year compared to those who used stimulants in the past year but not to treat pain. Previous studies have shown that prescription stimulants could have some efficacy treating depression, especially when prescribed as adjuvants to traditional antidepressants; however, results have been mixed (Malhi et al., 2016; McIntyre et al., 2017; Rohde et al., 2020). Our findings indicate that *illicit* stimulants are used to treat pain among people with co-occurring depression. It is possible that stimulants are being used to self-

manage chronic pain, depressive symptoms, or both among this group. The use of illicit stimulants for the potential self-management of depression deserves further exploration.

Our study has several limitations. All study participants were prescribed opioids for chronic pain during the past year, had a history of illicit substance use, and were enrolled in a safety-net health plan from the San Francisco Bay Area. Results may not necessarily be generalizable to all patients with CNCP. Furthermore, results may not be generalizable to other populations with a high prevalence of methamphetamine use that were not sufficiently represented in our cohort, such as people who are transgender (Reback and Fletcher, 2014; Santos et al., 2014). Data are self-reported and concern sensitive and illegal behaviors, and thus may be impacted by recall or social desirability bias. The baseline data were cross-sectional, not allowing for full evaluation of the temporality of pain and stimulant use. Finally, we did not measure concurrent or sequential use of opioids and stimulants, and did not ask about how participants' stimulant use to treat pain intersected with their prescribed pain medications. Future studies should investigate polysubstance use for non-medical reasons or for self-medication.

To our knowledge, this is the first report focusing on stimulant use for pain self-management. Our findings provide an opening for providers to engage in discussions with their patients regarding their use of stimulants as possibly part of pain self-management routines. Understanding individuals'

motivations for and benefits from using substances may aid in destigmatizing substance use, which is particularly important as stigma related to substance use can lead to decreased engagement in care and negative health outcomes (van Boekel et al., 2013). Further research exploring the ways that people who use illicit substances manage their own health and symptoms, including through illicit substances, is essential to reduce stigma, support effective provider-patient conversations, and identify unmet needs of people who use stimulants and experience chronic pain.

Tables and Figures

Table 1 . Baseline Demographic Characteristics Among Participants who Have Used Stimulants in the Past Year by Whether they Used Stimulants to Treat Pain in the Past Year (N=105)

	Participants Who Have Used Stimulants to Treat Pain in the Past Year (n=55)		Participants Who Have Not Used Stimulants to Treat Pain in the Past Year (n=50)		<i>p</i> -value
	n	%	n	%	
Age (mean, SD)	55 (8.8)		56 (8.2)		0.41
Assigned Sex at Birth					0.13
Male	36	65%	39	78%	
Female	19	35%	10	20%	
Intersex	0	0%	1	2%	
Gender					0.31
Male	35	64%	37	74%	
Female	18	33%	10	20%	
Transgender and Other	2	4%	3	6%	
Race					0.46
White, Caucasian, or European American	23	42%	16	32%	
African American or Black	19	35%	23	46%	
Other	13	24%	11	22%	
Ethnicity †					0.88
Non-Latino/Non-Hispanic	47	87%	44	88%	
Latino/Hispanic	7	13%	6	12%	
HIV Status					0.47
Negative	27	49%	21	42%	
Positive	28	51%	29	58%	
Education					0.04
HS/GED or less	21	38%	29	58%	
Some college or more	34	62%	21	42%	

Income					0.08
\$0-9,999	12	22%	7	14%	
\$10,000-\$19,999	39	71%	32	64%	
> \$20,000	4	7%	11	22%	
Ever Homeless					0.03
No	4	7%	11	22%	
Yes	51	93%	39	78%	

† There was one missing response for ethnicity.

Table 2. Pain Characteristics, Therapies, Substance Use, and Self-Reported Symptoms Among Participants who Have Used Stimulants in the Past Year by Whether they Used Stimulants to Treat Pain in the Past Year (N=105)

	Participants Who Have Used Stimulants to Treat Pain in the Past Year (n=55)		Participants Who Have Not Used Stimulants to Treat Pain in the Past Year (n=50)		<i>p</i> -value
	n	%	n	%	
Pain Characteristics					
Pain on average in past 3 months (mdn, IQR)	8 (7-9)		7 (6-8)		0.049
Pain catastrophizing					0.38
Score <30	34	62%	35	70%	
Score ≥ 30	21	38%	15	30%	
Neuropathic pain score †					0.13
No neuropathic pain	17	32%	22	47%	
Neuropathic pain	36	68%	25	53%	
DN4 score (mean, SD)	4.45	2.28	3.42	2.04	0.017
Cold pressor test †					
Cold pain threshold (sec) (mdn, IQR)	7.48	(5.21-11.93)	8.03	(5.5-10.44)	0.93
Cold pain tolerance (sec) (mdn, IQR)	13.19	(7.98-20.7)	12.96	(8.61-18.9)	0.87
Non-Opioid Medications & Complementary Therapies					
Non-opioid medications currently prescribed to treat pain					
None	13	24%	19	38%	0.11
Neuropathic pain medications	32	58%	23	46%	0.21

Medical Marijuana	16	29%	12	24%	0.56
Other non-opioid medications to treat pain	23	42%	10	20%	0.016
Complementary/Alternative therapies ^{††}					0.82
None in the past year	32	58%	28	56%	
Any in the past year	23	42%	22	44%	

Substance Use and Opioid Prescription Medications

Frequency of stimulant use					0.29
Less than weekly	24	44%	27	54%	
At least weekly	31	56%	23	46%	
Past year injection drug use					0.14
No injection in past year	25	45%	30	60%	
Injection in past year	30	55%	20	40%	
Heroin use					0.22
Did not use heroin in past year	31	56%	34	68%	
Used heroin in the past year	24	44%	16	32%	
Maximum MME in past year (mdn, IQR)	180 (69-305)		164 (68-300)		0.72
Opioid Prescription Discontinuation					0.65
Not discontinued in past year	42	76%	40	80%	
Discontinued in past year	13	24%	10	20%	

Self-reported Symptoms

Brief symptom inventory (BSI-18)					
BSI score (mdn, IQR)	16.0 (12-29)		12.5 (5-29)		0.086
Anxiety items	4.0 (2-5)		3.0 (1-6)		0.33

PTSD on Primary Care PTSD Screen (PC-PTSD)					0.67
No PTSD	33	60%	32	64%	
PTSD	22	40%	18	36%	
Depression scale (PHQ-8)					0.027
No or mild depression (<10)	28	51%	36	72%	
Moderate or severe depression (≥ 10)	27	49%	14	28%	

† Five participants did not do the neuropathic pain assessment and eight did not complete the cold pressor test.

†† Complementary/alternative therapies include chiropractic care, physical or occupational therapy, acupuncture, massage therapy, and group or individual counseling.

Table 3. Results of Multivariable Logistic Regression Analyses of Participant Characteristics Associated with Reporting Stimulant Use to Treat Pain in the Past Year Among Participants Who Used Stimulants in the Past Year (n=100)

Characteristics	AOR	95% CI	p-value
Increase in 10 years of age	1.04	(0.54-2.02)	0.90
Gender			
Male gender	ref	ref	ref
Female gender	3.20	(1.06-9.63)	0.039
Transgender/other gender	1.24	(0.14-10.75)	0.85
Race			
White, Caucasian, or European American	ref	ref	ref
African American or Black	0.39	(0.11-1.37)	0.14
Other race	0.64	(0.18-2.31)	0.49
Some college or more	2.02	(0.75-5.45)	0.17
Ever homeless	3.91	(0.98-15.62)	0.054
Average pain	1.18	(0.90-1.55)	0.22
Depression	1.51	(0.56-4.11)	0.42
Neuropathic assessment score	1.34	(1.05-1.70)	0.017
Other non-opiate medications to treat pain	2.25	(0.80-6.27)	0.12

References

- Ahmadian-Moghadam, H., Sadat-Shirazi, M.S., Zarrindast, M.R., 2018. Cocaine- and amphetamine-regulated transcript (CART): A multifaceted neuropeptide. *Peptides* 110, 56-77.
- Al-Tayyib, A., Koester, S., Langegger, S., Raville, L., 2017. Heroin and Methamphetamine Injection: An Emerging Drug Use Pattern. *Subst Use Misuse* 52(8), 1051-1058.
- Behar, E., Bagnulo, R., Knight, K., Santos, G.M., Coffin, P.O., 2020. "Chasing the pain relief, not the high": Experiences managing pain after opioid reductions among patients with HIV and a history of substance use. *PLoS One* 15(3), e0230408.
- Bouhassira, D., Attal, N., Alchaar, H., Boureau, F., Brochet, B., Bruxelle, J., Cunin, G., Fermanian, J., Ginies, P., Grun-Overdyking, A., Jafari-Schluep, H., Lanteri-Minet, M., Laurent, B., Mick, G., Serrie, A., Valade, D., Vicaut, E., 2005. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). *Pain* 114(1-2), 29-36.
- Bouhassira, D., Lantéri-Minet, M., Attal, N., Laurent, B., Touboul, C., 2008. Prevalence of chronic pain with neuropathic characteristics in the general population. *Pain* 136(3), 380-387.
- Bungay, V., Malchy, L., Buxton, J.A., Johnson, J., Macpherson, D., Rosenfeld, T., 2006. Life with jib: A snapshot of street youth's use of crystal methamphetamine. *Addiction Research and Theory* 14(3), 235-251.
- Camarasa, J., Rates, S.G., Pubill, D., Escubedo, E., 2009. The involvement of nicotinic receptor subtypes in the locomotor activity and analgesia induced by methamphetamine in mice. *Behav Pharmacol* 20(7), 623-630.

Centers for Disease Control and Prevention, 2012. HIV Infection, Risk, Prevention, and Testing Behaviors among Persons Who Inject Drugs: National HIV Behavioral Surveillance Injection Drug Use 20 US Cities, 2012.

Centers for Disease Control and Prevention, 2015. HIV Infection, Risk, Prevention, and Testing Behaviors among Persons Who Inject Drugs: National HIV Behavioral Surveillance Injection Drug Use 20 US Cities, 2015.

Centers for Disease Control and Prevention, 2019. Calculating Total Daily Dose of Opioids for Safer Dosage https://www.cdc.gov/drugoverdose/pdf/prescribing/Guidelines_Factsheet-a.pdf.

Centers for Disease Control and Prevention, 2020. U.S. Opioid Prescribing Rate Maps. <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html>. (Accessed March 31, 2020).

Coffin, P.O., Rowe, C., Bierkamp, A., 2019. San Francisco Annual Report: Substance Use Pattern and Trends through 2018. San Francisco Department of Public Health.

Coffin, P.O., Rowe, C., Oman, N., Sinchek, K., Santos, G.M., M, F., Bagnulo, R., D, M., E, V., 2020. Illicit Opioid Use Following Change in Opioids Prescribed for Chronic Non-Malignant Pain. PLoS One.

Dahlhamer, J., Lucas, J., Zelaya, C., Nahin, R., Mackey, S., DeBar, L., Kerns, R., Korff, M.V., Porter, L., Helmick, C., 2018. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016. MMWR Morb Mortal Wkly Rep 67, 1001-1006.

Derogatis, L.R., Fitzpatrick, M., 2004. The SCL-90-R, the Brief Symptom Inventory (BSI), and the BSI-18, in: Maurish ME (Ed.) The use of psychological testing for treatment planning and outcomes assessment : Volume 3: Instruments for Adults. pp. 1-41.

Dieleman, J.P., Kerklaan, J., Huygen, F.J., Bouma, P.A., Sturkenboom, M.C., 2008. Incidence rates and treatment of neuropathic pain conditions in the general population. *Pain* 137(3), 681-688.

Forrest, W.H., Jr., Brown, B.W., Jr., Brown, C.R., Defalque, R., Gold, M., Gordon, H.E., James, K.E., Katz, J., Mahler, D.L., Schroff, P., Teutsch, G., 1977. Dextroamphetamine with morphine for the treatment of postoperative pain. *N Engl J Med* 296(13), 712-715.

Jasinski, D.R., Preston, K.L., 1986. Evaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects. *Drug Alcohol Depend* 17(1), 1-13.

John, W.S., Wu, L.T., 2017. Trends and correlates of cocaine use and cocaine use disorder in the United States from 2011 to 2015. *Drug Alcohol Depend* 180, 376-384.

Kroenke, K., Spitzer, R.L., Williams, J.B., 2001. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 16(9), 606-613.

Kroenke, K., Strine, T.W., Spitzer, R.L., Williams, J.B., Berry, J.T., Mokdad, A.H., 2009. The PHQ-8 as a measure of current depression in the general population. *J Affect Disord* 114(1-3), 163-173.

Lin, Y., Morrow, T.J., Kiritsy-Roy, J.A., Terry, L.C., Casey, K.L., 1989. Cocaine: evidence for supraspinal, dopamine-mediated, non-opiate analgesia. *Brain Res* 479(2), 306-312.

Malhi, G.S., Byrow, Y., Bassett, D., Boyce, P., Hopwood, M., Lyndon, W., Mulder, R., Porter, R., Singh, A., Murray, G., 2016. Stimulants for depression: On the up and up? *Australian & New Zealand Journal of Psychiatry* 50(3), 203-207.

McIntyre, R.S., Lee, Y., Zhou, A.J., Rosenblat, J.D., Peters, E.M., Lam, R.W., Kennedy, S.H., Rong, C., Jerrell, J.M., 2017. The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis. *Journal of clinical psychopharmacology* 37(4), 412-418.

Merlin, J.S., Walcott, M., Kerns, R., Bair, M.J., Burgio, K.L., Turan, J.M., 2015. Pain self-management in HIV-infected individuals with chronic pain: a qualitative study. *Pain Med* 16(4), 706-714.

Michael J.L Sullivan, 1995. *The Pain Catastrophizing Scale: User Manual*.

Modir, J.G., Wallace, M.S., 2010. Human experimental pain models 2: the cold pressor model. *Methods Mol Biol* 617, 165-168.

Nielsen, S., Degenhardt, L., Hoban, B., Gisev, N., 2016. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. *Pharmacoepidemiol Drug Saf* 25(6), 733-737.

Oaks, Z., Stage, A., Middleton, B., Faraone, S., Johnson, B., 2018. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone. *Discov Med* 26(144), 197-206.

Prins, A., Ouimette, P., Kimerling, R., Cameron, R.P., Hugelshofer, D.S., Shaw-Hegwer, J., Thrailkill, A., Gusman, F.D., Sheikh, J.I., 2003. The primary care PTSD screen (PC-PTSD): development and operating characteristics *Primary Care Psychiatry* 9(1), 9-14.

Pud, D., Broitman, E., Hameed, O., Suzan, E., Aviram, J., Haddad, M., Hadad, S., Shemesh, R., Eisenberg, E., 2017. Methylphenidate attenuates the response to cold pain but not to aversive auditory stimuli in healthy human: a double-blind randomized controlled study. *Pain Rep* 2(3), e593.

Reback, C.J., Fletcher, J.B., 2014. HIV prevalence, substance use, and sexual risk behaviors among transgender women recruited through outreach. *AIDS Behav* 18(7), 1359-1367.

Robinson, J., Sareen, J., Cox, B.J., Bolton, J., 2009. Self-medication of anxiety disorders with alcohol and drugs: Results from a nationally representative sample. *Journal of Anxiety Disorders* 23(1), 38-45.

Robinson, L., Rempel, H., 2006. Methamphetamine use and HIV symptom self-management. *J Assoc Nurses AIDS Care* 17(5), 7-14.

Rohde, C., Brink, P., Østergaard, S.D., Nielsen, J., 2020. The use of stimulants in depression: Results from a self-controlled register study. *Aust N Z J Psychiatry*, 4867420924076.

Santos, G.M., Rapues, J., Wilson, E.C., Macias, O., Packer, T., Colfax, G., Raymond, H.F., 2014. Alcohol and substance use among transgender women in San Francisco: prevalence and association with human immunodeficiency virus infection. *Drug Alcohol Rev* 33(3), 287-295.

Spallone, V., Morganti, R., D'Amato, C., Greco, C., Cacciotti, L., Marfia, G.A., 2012. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. *Diabet Med* 29(5), 578-585.

Spoont, M.R., Williams, J.W., Jr., Kehle-Forbes, S., Nieuwsma, J.A., Mann-Wrobel, M.C., Gross, R., 2015. Does This Patient Have Posttraumatic Stress Disorder?: Rational Clinical Examination Systematic Review. *Jama* 314(5), 501-510.

Torrance, N., Smith, B.H., Bennett, M.I., Lee, A.J., 2006. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. *J Pain* 7(4), 281-289.

Treister, R., Eisenberg, E., Demeter, N., Pud, D., 2015. Alterations in pain response are partially reversed by methylphenidate (Ritalin) in adults with attention deficit hyperactivity disorder (ADHD). *Pain Pract* 15(1), 4-11.

Upadhyaya, M.A., Dandekar, M.P., Kokare, D.M., Singru, P.S., Subhedar, N.K., 2011. Evidence for the participation of cocaine- and amphetamine-regulated transcript peptide (CART) in the fluoxetine-induced anti-hyperalgesia in neuropathic rats. *Peptides* 32(2), 317-326.

van Boekel, L.C., Brouwers, E.P., van Weeghel, J., Garretsen, H.F., 2013. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. *Drug Alcohol Depend* 131(1-2), 23-35.

Voon, P., Callon, C., Nguyen, P., Dobrer, S., Montaner, J., Wood, E., Kerr, T., 2014. Self-management of pain among people who inject drugs in Vancouver. *Pain Manag* 4(1), 27-35.

Wu, Y., Levis, B., Riehm, K.E., Saadat, N., Levis, A.W., Azar, M., Rice, D.B., Boruff, J., Cuijpers, P., Gilbody, S., Ioannidis, J.P.A., Kloda, L.A., McMillan, D., Patten, S.B., Shrier, I., Ziegelstein, R.C., Akena, D.H., Arroll, B., Ayalon, L., Baradaran, H.R., Baron, M., Bombardier, C.H., Butterworth, P., Carter, G., Chagas, M.H., Chan, J.C.N., Cholera, R., Conwell, Y., de Man-van Ginkel, J.M., Fann, J.R., Fischer, F.H., Fung, D., Gelaye, B., Goodyear-Smith, F., Greeno, C.G., Hall, B.J., Harrison, P.A., Harter, M., Hegerl, U., Hides, L., Hobfoll, S.E., Hudson, M., Hyphantis, T., Inagaki, M.D., Jette, N., Khamseh, M.E., Kiely, K.M., Kwan, Y., Lamers, F., Liu, S.I., Lotrakul, M., Loureiro, S.R., Lowe, B., McGuire, A., Mohd-Sidik, S., Munhoz, T.N., Muramatsu, K., Osorio, F.L., Patel, V., Pence, B.W., Persoons, P., Picardi, A., Reuter, K., Rooney, A.G., Santos, I.S., Shaaban, J., Sidebottom, A., Simning, A., Stafford, M.D., Sung, S., Tan, P.L.L., Turner, A., van Weert, H.C., White, J., Whooley, M.A., Winkley, K., Yamada, M., Benedetti, A., Thombs, B.D., 2019. Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. *Psychol Med*, 1-13.